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Abstract The Generation R Study is a population-based
prospective cohort study from fetal life until young adult-
hood. The study is designed to identify early environmental
and genetic causes of normal and abnormal growth,
development and health from fetal life until young adult-
hood. In total, 9,778 mothers were enrolled in the study.
Prenatal and postnatal data collection is conducted by
physical examinations, questionnaires, interviews, ultra-
sound examinations and biological samples. Major efforts
have been conducted for collecting biological specimens
including DNA, blood for phenotypes and urine samples.
In this paper, the collection, processing and storage of these
biological specimens are described. Together with detailed
phenotype measurements, these biological specimens form
a unique resource for epidemiological studies focused on
environmental exposures, genetic determinants and their
interactions in relation to growth, health and development
from fetal life onwards.
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Introduction
The Generation R Study is a population-based prospective
cohort study from fetal life until young adulthood. The
background and speciﬁc research projects of the study have
been described in detail previously [1, 2]. Brieﬂy, the
Generation R Study is designed to identify early environ-
mental and genetic causes of normal and abnormal growth,
development and health from fetal life until young adult-
hood. The study focuses on four primary areas of research:
(1) growth and physical development; (2) behavioural and
cognitive development; (3) diseases in childhood; and (4)
health and healthcare for pregnant women and children.
The main outcomes and determinants are presented in
Tables 1 and 2. The general aims of the study are:
(1) To describe normal and abnormal growth, develop-
ment and health from fetal life until young adulthood;
(2) To identify biological, environmental and social
determinants of normal and abnormal growth,
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adulthood;
(3) To examine the effectiveness of current strategies for
prevention and early identiﬁcation of groups at risk.
For these aims, a detailed and extensive data collection
has been conducted in the prenatal phase of the study and is
currently conducted in the early postnatal period [2]. This
data collection comprises also biological specimens
including DNA, blood for phenotypes and urine samples.
These biological specimens form the Generation R Study
Biobank, which enables future epidemiological studies
focused on environmental exposures, genetic determinants
and their interactions in relation to growth, health and
development from fetal life onwards. In this paper, the
design, collection, processing and storage of these biolog-
ical specimens in the prenatal phase of the study are
described.
Design and biological samples collection
The Generation R Study is a population-based prospective
cohort study from fetal life until young adulthood [2].
Mothers with a delivery date between April 2002 and
January 2006 were eligible. Enrolment was aimed in early
pregnancy but was allowed until birth of the child.
Extensive assessments were carried out in mothers and
their partners in pregnancy and are currently performed in
their children. Assessments in pregnancy were planned in
early pregnancy (gestational age \18 weeks), mid-preg-
nancy (gestational age 18–25 weeks) and late pregnancy
(gestational age C25 weeks) and at birth. The individual
time scheme of these assessments depended on the speciﬁc
gestational age at enrolment [2]. The partners were asses-
sed once in pregnancy. All children form a prenatally
recruited birth-cohort that is currently being followed until
young adulthood.
Additionally, more detailed assessments of fetal and
postnatal growth and development are conducted in a
randomly selected subgroup of Dutch children and their
parents, referred to as the Generation R Focus Cohort.
Studies conducted in this subgroup examine etiological
associations using more time-consuming methods that
cannot be applied in the whole cohort.
Biological materials have been collected in early, mid-
and late pregnancy and at birth. Figure 1 shows the design
of the collection of biological materials in this phase. In
early, mid- and late pregnancy, biological materials were
collected at the visits to one of our dedicated research
centres. The planned amounts of blood taken by ante-
cubital venous puncture were 35 ml in early pregnancy and
20 ml in mid-pregnancy from the mother and 10 ml from
her partner. When mothers were enrolled in mid- and late
pregnancy, 35 ml was taken at the ﬁrst visit. Urine samples
of mothers have been collected in early, mid- and late
pregnancy from February 2004 until November 2005.
Directly after delivery, midwives or obstetricians collected
30 ml cord blood from the umbilical vein.
The Generation R Study is approved by the Medical
Ethical Committee of the Erasmus Medical Center, Rot-
terdam. Mothers and their partners received written and
Table 1 Main outcomes per research area
Growth and physical development
Fetal growth patterns and organ development
Pregnancy complications
Postnatal growth patterns
Obesity
Risk factors for development of cardiovascular disease
Risk factors for type 2 diabetes
Behavioural and cognitive development
Maternal and paternal psychopathology
Fetal and postnatal brain development
Behaviour, psychopathology and cognition
Neuromotor development
Chronic pain
Attachment
Stress reactivity
Diseases in childhood
Infectious diseases in childhood
Development of the immune system
Asthma and asthma related symptoms
Paroxysmal neurological disorders
Health and healthcare
Quality of life
Health care utilization
Effectiveness of screening programmes
Table 2 Main determinants
Biological determinants
Parental anthropometrics and blood pressure
Fetal and postnatal growth characteristics
Endocrine and immunological factors
Genetic variants
Environmental determinants
Maternal and childhood diet
Parental life style habits (including smoking, alcohol consumption)
Housing conditions
Social determinants
Parental education, employment status and household income
Parental marital status
Ethnicity
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123oral information about the study. Participants were asked
for their written informed.
Study cohort
In total, 9,778 mothers were enrolled in the study. Of these
mothers, 91% (n = 8,880) was enrolled in pregnancy.
Only partners from mothers enrolled during pregnancy
were invited to participate. In total, 71% (n = 6,347) of all
partners were enrolled. The general characteristics of the
mothers and their partners are presented in Table 3. Of all
participating mothers, enrolment was in early pregnancy in
69% (n = 6,748), in mid-pregnancy in 19% (n = 1,857),
in late pregnancy in 3% (n = 275) and at birth of their
child in 9% (n = 898). The cohort comprises various eth-
nic groups. The largest ethnic groups are the Dutch,
Surinamese, Turkish, Moroccan, Dutch-Antilles and Cape
Verdian mothers.
Logistics
All biological samples were bar coded with a unique lab-
oratory number. Blood or urine samples collected at one
visit have the same bar code with an additional speciﬁc
tube number. This combination forms a unique registration
number. All following steps in processing, storing and data
management of the samples are linked to this unique
number.
All blood samples from the mother and partner were
taken by research nurses and temporally stored at our
research centre or one of the obstetric departments at room
temperature for a maximum of 3 h. At least every 3 h,
these blood samples were transported to a dedicated labo-
ratory facility of the regional laboratory in Rotterdam, the
Netherlands (STAR-MDC) for further processing and
storage. Participants delivered their child either at home or
at one of the hospitals in Rotterdam. The midwife or
obstetrician collected cord blood samples. Subsequently,
courier services with a 7-days and 24-h availability were
responsible for transportation of these cord blood samples
to our laboratory within 2 h.
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Fig. 1 Design data collection biological specimens
Table 3 Characteristics of mothers and their partners
Mothers Partners
(n = 9,778) (n = 6,347)
Gestational age at enrolment (%)
Early pregnancy 69 –
Mid-pregnancy 19 –
Late pregnancy 3 –
Birth 9 –
Pregnancy number in study (%)
1st pregnancy 94 –
2nd pregnancy 6 –
3rd pregnancy 0.1 –
Age at enrolment (years)
a 29.7 (5.3) 32.7 (5.8)
Parity (%)
05 5 –
13 1 –
C21 4 –
Ethnicity (%)
Dutch, other-European 58 70
Surinamese 9 6
Moroccan 7 4
Turkish 9 6
Dutch Antilles 4 3
Cape Verdian 4 2
Others 9 9
Education (vocational training) (%)
Lower 13 8
Intermediate 45 41
Higher 42 51
Values are percentages
a Mean (standard deviation)
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123After collection and transportation, all blood and urine
samples have been centrally processed and stored at the
STAR-MDC laboratory. Samples for DNA extraction have
initially been stored as EDTA whole blood samples and
subsequently transported to the Erasmus Medical Center
for further processing.
All blood and urine samples are registered in Labosys
(Philips) [3]. Both the anonymous person unique study
numbers and all sample numbers are registered which
enables matching of each sample to a study subject. Also,
picking and defrosting of samples in registered in Labosys.
A back-up of this registration is available at the Erasmus
Medical Center.
Response rates
Response rates for collection of biological specimens are
presented in Table 4. Overall response rates for blood
collection in mothers are high. To get these high response
rates, we have used the venous punctures that were already
planned in routine care for additional blood sample col-
lection when this was possible. Blood for DNA extraction
is available in 91, 83 and 67% of the eligible mothers,
partners and children. The larger number of missings in
partners and children were mainly due to lack of consent
and logistical constraints during delivery, respectively. As
Table 4 shows, response rates for the various blood sam-
ples at one occasion were similar. Absolute numbers of
urine samples are lower than the absolute number of blood
samples because the urine sample collection was per-
formed during a limited period in the prenatal phase of the
study. Tables 5 and 6 show characteristics of children and
partners with and without available DNA. In children, the
number of missing blood samples in children with perinatal
complications including low birth weight and preterm birth
is higher because of the limited possibilities and priorities
Table 4 Response rates biological specimens
Eligible Available % (n)
Mother
DNA 8,880 91 (8,055)
Early pregnancy
Plasma (EDTA) 6,748 95 (6,398)
Serum 6,748 94 (6,337)
Urine 2,797 85 (2,375)
Mid-pregnancy
Plasma (EDTA) 8,241 93 (7,682)
Serum 8,241 93 (7,631)
Urine 3,380 97 (3,279)
Late-pregnancy
Urine 3,918 96 (3,762)
Partner
DNA 6,347 83 (5,289)
Child
DNA 8,821 67 (5,908)
Plasma (EDTA) 8,821 66 (5,857)
Serum 8,821 66 (5,821)
Number of eligible subjects reﬂects those participating in the study
during pregnancy (DNA mother and partner) and visit our research
centre in early, mid- or late pregnancy (plasma, serum and urine). The
number of eligible subjects for urine sample collection is lower since
this data-collection was added after starting the study. Number of
eligible children reﬂects the number of live born children of mothers
who were enrolled in the prenatal phase of the study with a known
date of birth
Table 5 Characteristics of partners with and without DNA available
Partners (n = 6,347)
DNA available
(n = 5,289)
No DNA available
(n = 1,058)
Age (years) 32.8 (5.7) 32.2 (5.7)
Ethnicity (%)
Dutch, other-European 68.2 66.1
Surinamese 6.8 6.6
Moroccan 3.8 6.2
Turkish 6.8 7.2
Dutch Antilles 2.9 3.4
Cape Verdian 2.7 1.9
Others 8.8 8.6
Values are percentages or means (standard deviation)
Table 6 Characteristics of children with and without DNA available
Children (n = 8,821)
DNA available
(n = 5,908)
No DNA available
(n = 2,913)
Male (%) 50.6 50.1
Birth weight (grams) 3,444 (520) 3,280 (671)
Birth weight\2,500 g (%) 3.3 10.8
Gestational age (weeks) 40.1 (37.1–
42.0)
39.9 (34.7–42.1)
Gestational age\37 weeks
(%)
3.9 11.2
Ethnicity (%)
Dutch, other-European 64.7 54.6
Surinamese 7.4 9.0
Moroccan 6.5 7.9
Turkish 7.5 9.5
Dutch Antilles 3.8 4.8
Cape Verdian 2.4 3.5
Others 7.7 10.7
Values are percentages, means (standard deviation) or median (95%
range)
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123during these deliveries. At this moment, efforts are carried
out for completing DNA collection in the children by
buccal samples.
DNA
For DNA extraction, one 10 ml EDTA tube from mothers,
partners and children at birth have been collected and
stored directly as whole blood sample at -80C. After
completion of the blood sample collection, DNA extraction
was started from white blood cells. First, DNA extraction
from all children has been conducted manually using the
Qiagen FlexiGene Kit (Qiagen Hilden, Germany). Cur-
rently, DNA extraction from 5 ml whole blood samples
from the mothers and partners is performed by a Hamilton
STAR multi-channel robot using AGOWA magnetic bead
technology (at 72 samples per run) and is expected to be
ﬁnished in spring 2008.
Extracted DNA is automatically collected in stock tubes
(2DMatrix,Micronic)thatareorganizedin96-wellsformat,
but that can be individually addressed. These stock samples
are split into two tubes that are stored at different locations.
One of the stocks will then be used for normalising the DNA
concentrationsin96deepwell(DW)plates.Thisprotocol,as
well as other manipulations of the DNA samples are per-
formed on a Caliper ALH3000 pipetting robot (8/96/384
channels) with a Twister module and a 96/384 wells Tecan
GENios plus UV reader. In total, 90 DNA samples are nor-
malised per 96 DW plate with 6 water blancs per plate.
Additionally,arandomselectionof5%ofthetotalnumberof
samples are put into separate 96 DW plates, again with 6
blancs per plate, for control purposes. For normalisation,
sampleanddiluentvolumesareautomaticallycalculatedand
producedtoobtainequalDNAconcentrationsforallsamples
(25–50 ng/ll). From these stock 96-DW plates, 384 DW
plates are created, which comprise 24 blancs each. Subse-
quently, replica PCR plates (384 wells) with a concentration
of 1 ng/ll are created for genotype studies.
Stock 96-well plates (DW and 2D Matrix, Micronic) are
stored at -20C at two different locations within the Eras-
mus Medical Center (Genetic Epidemiology Laboratory,
Genetic Laboratory Internal Medicine). The 384 DW stock
and PCR plates are stored at the Genetic Laboratory Internal
Medicine, Erasmus Medical Center. All genotyping studies
with Generation R DNA material are performed in-house at
the high throughput genotyping facility in this Laboratory.
Genome Wide Association database
A new approach to identify most important common
genetic variants that contribute to explain variance in
phenotypes by a systematic analysis of our genome has
only recently become available as the Genome Wide
Association (GWA) analysis [4]. The GWA analysis is
now generally considered a critical tool to identify genes
for complex diseases and traits. The GWA analysis is
based on genotyping large numbers ([500,000–2,000,000)
of Single Nucleotide Polymorphisms (SNPs), and subse-
quently performing association analyses of the SNP
genotypes (or haplotypes thereof) with the phenotype of
interest. The power of GWA analyses has been recently
demonstrated with the identiﬁcation of susceptibility
genes involved in a wide range of disorders varying from
common and rare diseases including coronary heart dis-
ease, diabetes and multiple sclerosis [5–7]. These
developments have led to a stream of novel disease genes,
highlighting new etiological pathways and are expected to
improve the understanding of the molecular basis of these
diseases. Currently, we are preparing a GWA analysis in
all children participating in the Generation R Study of
whom DNA is available. For this, the infrastructure, used
for the GWA analysis in Rotterdam Study, a population-
based cohort study in about 15,000 adults in Rotterdam,
the Netherlands is used [8].
Blood for phenotypes
Results of analyses performed in blood samples (5 ml
EDTA plasma) for routine care for pregnant women (Hb,
Ht, HIV, HBsAg, Lues, Rhesus factor and irregular anti-
bodies) are obtained from midwife and obstetric registries.
All other EDTA plasma and serum samples from
mothers and children have been processed and stored for
future studies. Processing was aimed to be ﬁnished
within a maximum of 3 h after venous puncture. Total
processing time took 15 min. The samples were spun and
the plasma and serum volume was distributed into 250 ll
aliquots and transferred to 0.65 ml polypropylene tubes
(Micronic) by a Tecan automatic liquid handler. From the
mother, a set of on average 16 aliquots tubes (with a
total volume of 4 ml) each from one plasma and serum
sample were divided over four different microtiter trays.
From the plasma and serum samples from the children,
on average 11 tubes were ﬁlled with 250 ll aliquots (in
total 2.75 ml) divided over three microtiter trays. The
trays were immediately stored at -80C. Each Micronic
tube is uniquely coded on the bottom with the Traxis

2D code.
The aliquots were divided over 4 trays of 96 tubes for
storage in the freezers. Figure 2 shows the distribution of
the samples in the 96 trays. All samples are stored at -
80C at one location (STAR-MDC laboratory) where they
The Generation R Study Biobank 921
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power supplies.
Urine
Urine samples (65 ml) were added to the data collection
between February 2004 and November 2005. The urine
samples were kept at room temperature for a maximum of
3 h and transported to the STAR-MDC laboratory for
further processing. At the laboratory, the urine was ﬁlled
out manually in one 5 ml and three 20 ml tubes. Before the
urine was ﬁlled out, a gravity measurement was performed.
The 5 ml urine tubes were send to the Department of
Medical Microbiology of the Erasmus Medical Centre for
Chlamydia analysis [9]. The remaining urine tubes (20 ml)
were each stored at -20C at the STAR-MDC laboratory.
Other population-based birth cohort studies
The Generation R Study is not the ﬁrst birth-cohort study
with an extensive collection of biological specimens.
Compared to other birth-cohort studies, the size of the
Generation R Study cohort is not larger but the measure-
ments are more detailed and the study group has a large
ethnic variety [10–14]. Studies having a similar design and
biological specimens collection include the Avon Longi-
tudinal Study of Parents and Children (ALSPAC) in
Bristol, UK, the Danish National Birth Cohort Study, the
Norwegian mother and child Cohort Study, the South-
ampton Women’s Survey (SWS) in Southampton, UK and
The National Children’s Study in the USA.
Collaboration with these studies for funding, standardi-
zation, replication and quality management is necessary.
Currently, we are exploring possibilities for formal
collaboration.
Requests for biological samples use
The study has an open policy with regard to collaboration
with other research groups. Request for collaboration and
use of biological specimens should primarily be pointed to
Albert Hofman (a.hofman@erasmusmc.nl). These requests
are discussed in the Generation R Study Management
Team regarding their scientiﬁc merits, study aims, overlap
with ongoing studies, logistic consequences and ﬁnancial
contributions.
General policy is that collaborating researchers and
groups are responsible themselves for the ﬁnances and that
all laboratory tests are conducted in the Eramus Medical
Center, Rotterdam. After approval of the project by the
Generation R Study Management Team and the Medical
Ethical Committee of the Erasmus Medical Center, the
collaborative research project is embedded in one of the
four research areas supervised by the speciﬁc principal
investigator.
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